论文部分内容阅读
目的:探讨冠心病患者经皮冠状动脉介入术(PCI)术后联合应用尼可地尔与阿托伐他汀的治疗效果。方法:抽取2018年2月至2019年10月山西省心血管病医院收治的83例冠心病PCI术后患者，经随机数字表法分为观察组(42例)和对照组(41例)，对照组术后予以阿托伐他汀治疗，观察组术后予以尼可地尔联合阿托伐他汀治疗。比较两组治疗效果，治疗前后心脏功能、心肌损伤标志物、血管内皮功能、不良心血管事件及不良反应。结果:观察组总有效率(92.86%)优于对照组的75.61%(n P<0.05)；观察组治疗后左室舒张末内径、左室收缩末内径为(42.15±4.28)mm、(29.12±2.49)mm，低于对照组的(46.37±4.86)mm、(32.25±3.06)mm(n P<0.05)，左室射血分数为(50.14±5.81)%，高于对照组的(54.86±6.57)%(n P<0.05)；观察组治疗后肌酸激酶同工酶、心肌肌钙蛋白I水平为(7.37±2.39)U/L、(0.45±0.11)μg/L，低于对照组的(11.84±3.01)U/L、(0.99±0.28)μg/L(n P<0.05)；观察组治疗后一氧化氮水平为(71.92±5.82)μmol/L，高于对照组的(117.25±13.11)μmol/L(n P<0.05)，内皮素-1水平为(101.34±11.06)ng/L，低于对照组的(117.25±13.11)ng/L(n P<0.05)；观察组不良心血管事件发生率为4.76%，低于对照组的19.51%(n P<0.05)；两组治疗期间均未出现严重不良反应。n 结论:冠心病患者PCI术后联合应用尼可地尔与阿托伐他汀对心脏功能具有保护作用，能减少心肌损伤，改善血管内皮功能，降低不良心血管事件发生率，疗效确切，安全性高。“,”Objective:To investigate the effects of nicorandil combined with atorvastatin on cardiac function in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).Methods:A total of 83 patients with CHD undergoing PCI in Shanxi Cardiovascular Hospital were enrolled from February 2018 to October 2019 were selected. They were divided into observation group (42 cases) and control group (41 cases) by random number table method. The control group was treated with atorvastatin, while the observation group was treated with nicorandil and atorvastatin. The clinical curative effect, cardiac function, myocardial injury markers, vascular endothelial function, adverse cardiovascular events and adverse reactions before and after treatment were compared between the two groups.Results:The total effective rate of the observation group (92.86%) was better than 75.61% of the control group (n P<0.05). The left ventricular end diastolic diameter and left ventricular end systolic diameter in the observation group were (42.15±4.28) mm and (29.12±2.49) mm, which were lower than (46.37±4.86) mm and (32.25±3.06) mm in the control group (n P<0.05), the left ventricular ejection fraction was (50.14±5.81)%, which was higher than (54.86±6.57)% in the control group(n P<0.05); after treatment, the levels of creatinekinase-MB and cardiac troponin I in the observation group were (7.37±2.39) U/L and (0.45±0.11) μg/L, which were lower than (11.84±3.01) U/L and (0.99±0.28) μg/L in the control group (n P<0.05); the level of nitric oxide in the observation group was (71.92±5.82) μmol / L, which was higher than (117.25±13.11)μmol/L in the control group, the level of endothelin-1 was (101.34±11.06) ng/L, which was lower than (117.25±13.11) ng/L in the control group (n P<0.05); the incidence of major adverse cardiovascular events in the observation group was 4.76%, which was lower than 19.51% in the control group(n P<0.05). There were no serious adverse reactions in both groups during treatment.n Conclusions:The combined application of nicorandil and atorvastatin in patients with coronary heart disease after PCI can protect cardiac function, reduce myocardial injury, improve vascular endothelial function and reduce the incidence of mace. It has definite curative effect and high safety.